Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present HedgePath Pharmaceuticals, Inc. (OTC: HPPI).

Full DD Report for HPPI

You must become a subscriber to view this report.


Recent News from (OTC: HPPI)

HedgePath Pharmaceuticals Announces Expanded Patent Coverage
TAMPA, Fla. , May 14, 2018 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that the U.S. Patent and Trademar...
Source: PR Newswire
Date: May, 14 2018 09:00
HedgePath Pharmaceuticals: What To Expect Next?
It's been nearly 4 months since HedgePath Pharmaceuticals ( HPPI ) has shared any news with investors. Best I can tell, the timeline of major events has not slipped at all, so this likely means there will be a lot of news for investors in a relatively compressed timeline over the remainder of ...
Source: SeekingAlpha
Date: May, 10 2018 16:14
Emerging Developments: New Research on HedgePath Pharmaceuticals and Kentucky Bancshares - A Look Ahead into 2018
NEW YORK, NY / ACCESSWIRE / March 6, 2018 / Latest key findings by Growth Market Report for all traders, shareholders, and investors of HedgePath Pharmaceuticals Inc. (OTCQX: HPPI) and Kentucky Bancshares Inc. (OTCQX: KTYB), including recent technical analysis and consolidated fundamental in...
Source: ACCESSWIRE IA
Date: March, 06 2018 07:30
HedgePath Pharmaceuticals: Some Primary Concerns Addressed And Mitigated Through Mayne Pharma Deal
On January 11, HedgePath Pharmaceuticals (HPPI) announced a funding agreement with its partner Mayne Pharmaceuticals ([[MAYNF]], [[MYPHY]]) and the modified terms of its important Supply and License Agreement with Mayne Pharmaceuticals. Both of these elements address the main concerns ȁ...
Source: SeekingAlpha
Date: January, 12 2018 11:52
HedgePath Pharmaceuticals Secures New Funding from Mayne Pharma to Support BCCNS Clinical and Regulatory Approval Programs
TAMPA, Fla. , Jan. 11, 2018 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQX:HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has entered into a defini...
Source: PR Newswire
Date: January, 11 2018 08:30
HedgePath Pharmaceuticals - Undiscovered, Underfollowed, And Undervalued
Note: Be advised that this article contains medical imagery that some might consider graphic. Background HedgePath Pharmaceuticals (HPPI) is a Tampa-based clinical stage biopharmaceutical company focused currently on repurposing the marketed antifungal drug itraconazole for new indic...
Source: SeekingAlpha
Date: November, 13 2017 11:34
HedgePath Pharmaceuticals Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update
TAMPA, Fla. , Oct. 30, 2017 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQX: HPPI), a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize innovative therapeutics for patients with cancer, announced today that it has completed enrollment...
Source: PR Newswire
Date: October, 30 2017 09:00
HedgePath Pharmaceuticals, Inc. Presentation Now Available for On-Demand Viewing
HedgePath Pharmaceuticals, Inc. Presentation Now Available for On-Demand Viewing Canada NewsWire TAMPA, Fla., Oct. 9, 2017 Company invites individual and institutional investors as well as advisors to log-on to VirtualInvestorConferences.com to view presentation TAMPA...
Source: Canada Newswire
Date: October, 09 2017 08:31
HedgePath Pharmaceuticals (HPPI) Presents At Virtual Investor Conference - Slideshow
The following slide deck was published by HedgePath Pharmaceuticals, Inc. in conjunction with this Read more ...
Source: SeekingAlpha
Date: October, 06 2017 11:47
HedgePath Pharmaceuticals, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 5
HedgePath Pharmaceuticals, Inc. to Webcast, Live, at VirtualInvestorConferences.com October 5 Canada NewsWire TAMPA, Fla., Sept. 28, 2017 Company invites individual and institutional investors as well as advisors to attend interactive real-time virtual VirtualInvestorC...
Source: Canada Newswire
Date: September, 28 2017 08:35

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-16N/A0.30N/AN/A0
2018-08-150.2850.300.300.28513,122
2018-08-140.2990.2850.2990.28510,000
2018-08-13N/A0.298N/AN/A0
2018-08-10N/A0.298N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1512,50113,12295.2675Short
2018-08-147,50010,00075.0000Short
2018-08-097,0007,000100.0000Short
2018-08-075,95711,58751.4111Short
2018-08-064,0367,72652.2392Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on HPPI.


About HedgePath Pharmaceuticals, Inc. (OTC: HPPI)

Logo for HedgePath Pharmaceuticals, Inc. (OTC: HPPI)

HedgePath Pharmaceuticals is a biopharmaceutical company that is seeking to discover, develop and commercialize innovative therapeutics for patients with certain cancers

 

Contact Information

 

 

Current Management

  • Nicholas Virca / CEO, President
  • Garrison J. Hasara / CFO, Treasurer
  • James McNulty / Secretary, Compliance Officer
  • E. Brendan Magrab / Chairman
  • Stefan Cross / Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Robert D Martin / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • Dana Ono / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member
  • W. Mark Watson / Independent Director, Audit Committee Member, Compensation Committee Member, Nominating Committee Member

Current Share Structure

  • Market Cap: $114,575,772 - 03/09/2018
  • Authorized: 500,000,000 - 02/28/2018
  • Issue and Outstanding: 369,599,266 - 02/28/2018
  • Float: 77,572,902 - 02/28/2018

 


Recent Filings from (OTC: HPPI)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 01 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 17 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: April, 04 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 16 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: January, 22 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: January, 11 2018
Amendment to a SC 13D filing
Filing Type: SC 13D/AFiling Source: edgar
Filing Date: January, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: December, 20 2017
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: November, 13 2017
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: October, 31 2017

 

 


Daily Technical Chart for (OTC: HPPI)

Daily Technical Chart for (OTC: HPPI)


Stay tuned for daily updates and more on (OTC: HPPI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: HPPI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in HPPI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of HPPI and does not buy, sell, or trade any shares of HPPI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/